Palboxen 125 mg (Palbociclib) Capsules

Palboxen 125 mg should be taken only according to the prescribing oncologist's instructions. Palbociclib treatment commonly follows a scheduled treatment cycle rather than continuous daily administration.

Standard Adult Dose

The commonly recommended starting dose of palbociclib for eligible adult patients is:

125 mg once daily for 21 consecutive days, followed by 7 days without treatment, creating a 28-day treatment cycle.

The medicine is normally administered in combination with the prescribed endocrine therapy. Depending on tolerability, blood counts, liver function, drug interactions, and other clinical factors, the oncologist may reduce or interrupt the palbociclib dose.

Common dose-reduction levels may include:

• Starting dose: 125 mg once daily
• First dose reduction: 100 mg once daily
• Second dose reduction: 75 mg once daily

A healthcare professional should determine whether treatment interruption or dose reduction is necessary.

How to Take Palbociclib

• Take the capsule at approximately the same time each day.
• Swallow the capsule whole with water.
• Do not crush, chew, open, or dissolve the capsule.
• Follow the prescribed 21-days-on/7-days-off schedule unless your oncologist gives different instructions.
• Palbociclib may generally be taken with or without food, according to the prescribed formulation and product information.
• Avoid grapefruit, grapefruit juice, and products containing grapefruit unless your healthcare professional confirms they are appropriate, because grapefruit can affect palbociclib exposure.
• Do not change the dose or treatment schedule without medical advice.

Missed Dose

If vomiting occurs after taking a dose, do not take an additional capsule on the same day. The next dose should generally be taken at the usual scheduled time.

If a dose is missed or forgotten, do not double the next dose. Follow the instructions provided by the treating healthcare professional or the product's prescribing information.

Important Administration Guidance

Because palbociclib can reduce blood-cell production, patients usually require regular blood-count monitoring, particularly during the initial treatment cycles. Dose adjustments may be required if significant neutropenia or other treatment-related abnormalities occur.

Patients should promptly report symptoms such as fever, chills, unusual bleeding, persistent weakness, or signs of infection to their healthcare provider.

Important: The dose and treatment schedule can differ based on the patient's age, overall health, previous cancer treatment, concomitant medicines, liver function, blood counts, and tolerability. Palboxen should therefore be used strictly under specialist medical supervision.